NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell DeathData Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- ...
NuCana (NCNA) presented data at the European Society for Medical Oncology Congress 2025, ESMO, on a new model system investigating the synergistic ...
Efficacy and safety of regorafenib combined with PD-1 inhibitors in patients with advanced hepatocellular beyond atezolizumab plus bevacizumab: A retrospective analysis of real-world evidence. This is ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
10hon MSN
Celltrion Signs Joint Research and Development Agreement with MustBio for Multi-Antibody New Drug
Celltrion announced on the 31st that it has signed a joint research and development agreement for a new immuno-oncology drug with MustBio, a domestic ...
A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback